BioNano Genomics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Consumer Staples Select Sector SPDR Fund trades at $85.13. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | XLP | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | — |
52-Week High | $4.92 | $90.00 |
52-Week Low | $1.06 | $75.61 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
XLP trades at $85.08 with minimal daily movement (+0.15%), reflecting stable defensive positioning. Technical indicators show mixed signals with a neutral overall rating, while analyst consensus remains strongly bullish with 100% buy ratings. The consumer staples ETF benefits from recent positive sector momentum and defensive characteristics during market uncertainty.
The outlook remains positive given the defensive nature of consumer staples amid economic uncertainty, with potential for steady dividend income. Key risks include sector rotation away from defensive plays and valuation concerns if growth expectations moderate. The 2.6% dividend yield provides income support while awaiting capital appreciation.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →